Reuters logo
BRIEF-Tigenix announces Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction
March 13, 2017 / 6:23 AM / in 9 months

BRIEF-Tigenix announces Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction

March 13 (Reuters) - Tigenix NV:

* Announces Phase I/II results of AlloCSC-01 in Acute Myocardial Infarction

* All safety objectives of study have been met

* No mortality or major cardiac adverse events (MACE) have been found at 30 days meeting primary end-point of study

* No mortality or major cardiac adverse events have been found at 6 months or 12 months follow-up Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below